Carregant...
Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer
PURPOSE: In a recent Phase II clinical trial, low dose (100 mg/kg) gemcitabine showed promise as a radiosensitiser in bladder cancer but underlying mechanisms lack elucidation. Here we investigated the mechanism of radiosensitisation by low-dose gemcitabine in bladder cancer cell lines. EXPERIMENTAL...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4216732/ https://ncbi.nlm.nih.gov/pubmed/25224279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0542 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|